[Pancreatic polypeptide (author's transl)].
Pancreatic Polypeptide (PP) was first described in birds by Kimmel et al. (1968). It was later isolated from the pancreas of several mammalian species by Chance and Jones (1974). It has been demonstrated in the islets of many animal species by immunocytochemical methods. PP levels are assayable in plasma and rise sharply after food intake. The pharmacological properties and physiological role of PP are still ill defined. It appears to have a spectrum of actions peculiar to each species. Recent research on this subject is reviewed in this article. High levels of circulating PP have been demonstrated in juvenile and maturity-onset diabetics, as well as in some patients with islet cell tumors. However no definite clinical syndrome due to hypersecretion of PP as been identified as yet. It remains a matter of speculation that a deficiency of PP might be responsible for some types of obesity. PP-cells are rare in the pancreas of healthy young individuals. Hyperplasia of PP-cells has been observed in a wide variety of pathological conditions, but is most prominent in the pancreas of chronic insulin dependent diabetics. Histologic evidence strongly suggests that PP-cell hyperplasia represents an atypical form of islet regeneration. It is always focal in distribution and is most remarkable in those lobules that have lost the capacity to reproduce islets of normal cytologic composition.
D007516:Adenoma, Islet Cell / Q000503:physiopathology; D003594:Cytoplasmic Granules / Q000648:ultrastructure; D003920:Diabetes Mellitus / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D006801:Humans; D008854:Microscopy, Electron; D010179:Pancreas / Q000502:physiology / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000503:physiopathology; D010191:Pancreatic Polypeptide / Q000502:physiology
D010191:Pancreatic Polypeptide
Le polypeptide pancréatique.